UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045750
Receipt number R000052200
Scientific Title Effect of Daily Ingestion of the Barley on Improving Minor Health Complaints: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study
Date of disclosure of the study information 2021/10/20
Last modified on 2023/04/17 10:02:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Daily Ingestion of the Barley on Improving Minor Health Complaints: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study

Acronym

Beneficial Effect of the Barley on Improving Minor Health Complaints

Scientific Title

Effect of Daily Ingestion of the Barley on Improving Minor Health Complaints: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study

Scientific Title:Acronym

Beneficial Effect of the Barley on Improving Minor Health Complaints

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To prove improving minor health complaints and safety associated with 4 weeks daily ingestion of barley, in a double-blind, placebo-controlled, parallel group comparison study.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The Brief Job Stress Questionnaire (Section B) at 4 weeks after beginning the intake of test food.

Key secondary outcomes

Bowel diary, Intestinal flora, Organic acids in feces, Electroencephalogram during sleeping, Heart rate variability, survey on subjects' sleeping and mental and physical conditions.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Daily ingestion of 100 g steamed barley-1 for 4 weeks.

Interventions/Control_2

Daily ingestion of 100 g of steamed barley-2 for 4 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. Subjects who agree to participate in this study with a written informed consent.
2. Subjects with physical-mental minor complaints.
3. Subjects who agree to participate in the Observational study conducted by Hokkaido Information University Health Information Science Center.

Key exclusion criteria

1. Subjects who are under physician's advice, treatment, and/or medication for schizophrenia, depression, mania, neurological disorders, and/or sleep disorders.
2. Subjects with gastrointestinal disorders.
3. Subjects who take antihypertensive agents, immunosuppressive drugs, and/or indomethacin.
4. Subjects who used antibiotics within 12 wks, prior to the current study.
5. Subjects with implantable electronic medical devices.
6. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities.
7. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
8. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data.
9. Subjects with severe anemia.
10. Pre- or post-menopausal women complaining of obvious physical changes.
11. Subjects who are at risk of having allergic reactions to drugs or foods especially based on wheat.
12. Subjects who regularly take medicine, functional foods, and/or supplements which contains GABA.
13. Subjects who regularly use gastrointestinal drugs.
14. Subjects with defecation frequency less than 2 times per week.
15. Subjects who repeat constipation and diarrhea.
16. Heavy smokers, alcohol addicts or subjects with disordered lifestyle.
17. Subjects who donated either 400 ml whole blood within 16 wks (women), 12 wks (men), 200 ml whole blood within 4 wks, or blood components within 2 wks, prior to the current study.
18. Pregnant or lactating women or women who expect to be pregnant during this study.
19. Subjects who currently participate in other clinical trials, or participated within the last 4 wks prior to the current study.
20. Subjects whose lifestyle is expected to change significantly.
21. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Naoyuki
Middle name
Last name HONMA

Organization

Hokkaido Information University

Division name

Department of Medical Management and Informatics

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4430

Email

hisc-acad.res@s.do-johodai.ac.jp


Public contact

Name of contact person

1st name Naoyuki
Middle name
Last name HONMA

Organization

Hokkaido Information University

Division name

Health Information Science Center

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4430

Homepage URL


Email

hisc-acad.res@s.do-johodai.ac.jp


Sponsor or person

Institute

Hokkaido Information University

Institute

Department

Personal name



Funding Source

Organization

National Agriculture and Food Research Organization, bio-oriented technology Research Advancement Institution

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

National Agriculture and Food Research Organization
National Institutes of Biomedical Innovation, Health and Nutrition
National Institute of Advanced Industrial Science and Technology

Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethics committee of Hokkaido Information University

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

Tel

011-385-4411

Email

soumu@do-johodai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道情報大学 保健センター(北海道)


Other administrative information

Date of disclosure of the study information

2021 Year 10 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 09 Month 22 Day

Date of IRB

2021 Year 09 Month 22 Day

Anticipated trial start date

2021 Year 11 Month 15 Day

Last follow-up date

2022 Year 02 Month 17 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 10 Month 14 Day

Last modified on

2023 Year 04 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052200